Phaseline

Targets › DNAJB1

DNAJB1 (DnaJ homolog subfamily B member 1): drug programs, companies and trials

2 programs from 2 companies in 5 trials: 5 Phase 1; Oncology; next expected readout Jan 2027.

Interacts with HSP70 and can stimulate its ATPase activity. Acts also with TTC1 as a chaperone adapter that regulates HSP70-dependent folding process by interacting with the HSP70 amino terminal region. (UniProt, P25685)

Open in Phaseline: the race on DNAJB1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
University Hospital TuebingenFusion-VAC-XS15
DNAJB1-PRKACA fusion peptide vaccine with TLR1/2 agonist
DNAJB1, PRKACAPhase 1Fibrolamellar Hepatocellular Carcinoma; Fibrolamellar Hepatocellular Carcinoma (FLC)Jan 2027
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsDNAJB1-PRKACA Peptide Vaccine
Peptide vaccine targeting DNAJB1-PRKACA fusion kinase
DNAJB1, PRKACAPhase 1NSCLC Stage IV; Fibrolamellar Hepatocellular Carcinoma (FLC); Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC))Jul 2027

Conditions

Fibrolamellar Hepatocellular Carcinoma (FLC) (2) NSCLC Stage IV (1) Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC)) (1) Fibrolamellar Hepatocellular Carcinoma (1)

Modalities

mixed (1), other (1)

Companies

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) University Hospital Tuebingen (1)

Related targets

PRKACA (2)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.